Co-Diagnostics, Inc. Common Stock Total Assets
Co-Diagnostics, Inc. Common Stock total assets. Based on the latest financial reports, Co-Diagnostics, Inc. Common Stock (CODX) holds total assets worth $21.50 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Co-Diagnostics, Inc. Common Stock for the company's overall valuation and market capitalisation.
Total Assets of Co-Diagnostics, Inc. Common Stock (2014–2025)
Total assets of Co-Diagnostics, Inc. Common Stock from 2014 to 2025. This chart illustrates how Co-Diagnostics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See CODX stock price and chart for real-time trading data and today's change.
Co-Diagnostics, Inc. Common Stock - Asset Composition Analysis
Co-Diagnostics, Inc. Common Stock Total Assets Breakdown (December 2025)
Co-Diagnostics, Inc. Common Stock total assets breakdown as of December 2025. Co-Diagnostics, Inc. Common Stock's total assets of $21.50 Million consist of 55.3% current assets and 44.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 48.0% |
| Accounts Receivable | $190.38K | 0.8% |
| Inventory | $992.40K | 4.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.22 Million | 29.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Co-Diagnostics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Co-Diagnostics, Inc. Common Stock short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Co-Diagnostics, Inc. Common Stock's current assets represent 55.3% of total assets in 2025, a decrease from 85.6% in 2014.
- Cash Position: Cash and equivalents constituted 48.0% of total assets in 2025, down from 82.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 29.2% of total assets.
Co-Diagnostics, Inc. Common Stock Competitors by Total Assets
Key competitors of Co-Diagnostics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
BMC Medical Co. Ltd. A
SHE:301367
|
China | CN¥3.59 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Co-Diagnostics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.28 | 4.43 | 19.10 |
| Quick Ratio | 2.09 | 4.23 | 18.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.50 Million | $18.45 Million | $85.59 Million |
Co-Diagnostics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Co-Diagnostics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.30 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -61.3% |
| Total Assets | $24.74 Million |
| Market Capitalization | $1.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Co-Diagnostics, Inc. Common Stock's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Co-Diagnostics, Inc. Common Stock's assets decreased by 61.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Co-Diagnostics, Inc. Common Stock (2014–2025)
The table below shows the annual total assets of Co-Diagnostics, Inc. Common Stock from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $24.74 Million | -61.34% |
| 2024-12-31 | $64.00 Million | -32.86% |
| 2023-12-31 | $95.32 Million | -22.56% |
| 2022-12-31 | $123.09 Million | -23.09% |
| 2021-12-31 | $160.03 Million | +124.65% |
| 2020-12-31 | $71.24 Million | +3115.65% |
| 2019-12-31 | $2.22 Million | +42.63% |
| 2018-12-31 | $1.55 Million | -66.69% |
| 2017-12-31 | $4.66 Million | +259.80% |
| 2016-12-31 | $1.30 Million | +249.35% |
| 2015-12-31 | $370.93K | +42.75% |
| 2014-12-31 | $259.85K | -- |
About Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provide… Read more